skip to main content

NSAID exposure after 20 weeks of pregnancy — SCE Rheumatology MCQ

Instant feedback + full explanation. One question, done properly.

ModerateNSAIDNSAID exposure after 20 weeks of pregnancySCE Rheumatology

A 31-year-old woman with radiographic axial spondyloarthritis is 23+6 weeks pregnant. Her inflammatory disease is well controlled on certolizumab pegol. Nine days ago, she developed self-limiting mechanical pelvic girdle pain and restarted naproxen 500 mg twice daily from a previous prescription without seeking advice. She took the most recent dose this morning. The pain has now resolved. Her 20-week fetal anomaly scan was normal, and she reports normal fetal movements. She has no vaginal bleeding, hypertension or renal impairment. Which is the most appropriate NSAID-specific management plan?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: B — Stop naproxen now and liaise with the obstetric team to consider monitoring amniotic fluid volume and fetal ductal flow

Explanation lettering: E = shown as C · C = shown as E

The decisive features are exposure to a systemic NSAID after 20 weeks’ gestation, treatment for more than several days, and the absence of any continuing clinical indication. Naproxen should therefore be stopped. UK MHRA advice states that systemic NSAIDs should be avoided from week 20 unless clinically required and used at the lowest dose for the shortest duration. Following exposure for several days after week 20, antenatal monitoring for oligohydramnios should be considered; current product information also advises considering assessment for ductus arteriosus constriction. A is incorrect because 28 weeks is the threshold for contraindication, not a licence to continue unnecessary treatment between weeks 20 and 28. C applies dose minimisation but still prolongs exposure despite resolution of pain; a generic growth scan does not specifically address amniotic fluid and ductal effects. D is incorrect because changing to a cyclo-oxygenase-2-selective NSAID does not avoid the fetal prostaglandin-mediated class risks, and maternal creatinine monitoring alone is inadequate. E reflects an obsolete later stopping threshold and incorrectly uses fetal movements as reassurance: oligohydramnios or ductal constriction may not initially alter perceived movements. Systemic NSAIDs are contraindicated from the last trimester, defined in current UK regulatory advice as from 28 weeks.

Reference: Non-steroidal anti-inflammatory drugs (NSAIDs): potential risks following prolonged use after 20 weeks of pregnancy (27 June 2023) — https://www.gov.uk/drug-safety-update/non-steroidal-anti-inflammatory-drugs-nsaids-potential-risks-following-prolonged-use-after-20-weeks-of-pregnancy?UNLID=896746856202668162013 Ibuprofen 400 mg Soft Capsules — Summary of Product Characteristics (16 September 2024) — https://www.medicines.org.uk/emc/product/14695/smpc